サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363063

抗ウイルス薬の市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、流通チャネル別、用途別、地域別、セグメント予測、2023年～2030年

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
抗ウイルス薬の市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、流通チャネル別、用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月18日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗ウイルス薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗ウイルス薬市場規模は、2023年から2030年にかけてCAGR-1.99%を記録し、2030年までに620億5,000万米ドルに達すると予測されています。

この背景には、ウイルス性疾患の有病率の上昇と、感染症の蔓延を抑えるための新規治療薬の開発に関連する政府のイニシアチブの高まりがあります。さらに、研究開発努力の増加や、予防接種や併用療法など、より新しく最新の詳細の拡大が、市場の成長を促進すると予測されています。ウイルスのパンデミックの可能性は、適切な予防接種ができるまでウイルスの蔓延を食い止めるために、即座に大規模に展開できる直接作用型抗ウイルス薬などの広域抗ウイルス薬の必要性を浮き彫りにしています。抗ウイルス薬のブロックバスター治療薬の登場は、さまざまなウイルス感染症の治療に変革をもたらしました。

顕著な例として、ソバルディ（ソホスブビル）、ハーボニー（レディパスビル／ソホスブビル）、エプクローサ（ソホスブビル／ベルパタスビル）といったC型肝炎治療薬の直接作用型抗ウイルス薬（DAAs）のインダクションがあり、従来の治療薬に比べて高い治癒率、治療期間の短縮、副作用の軽減を実現し、この分野に革命をもたらしました。これらの薬剤は、C型肝炎の治癒に有効であり、アンメット・メディカル・ニーズに応えるものであるため、ブロックバスターの地位を獲得しました。抗ウイルス薬に対する政府の取り組みには、研究開発への資金提供、承認や緊急使用認可のための規制プロセスの合理化、備えのための戦略的備蓄、効果的な抗ウイルス治療薬の開発を加速させ入手しやすくするための産業界や学術機関との協力などがあります。

例えば、2022年5月、米国立衛生研究所の一部である米国立アレルギー感染症研究所（NIAID）は、パンデミックが懸念される病原体のための9つの抗ウイルス薬発見（AViDD）センターを立ち上げるため、約5億7,700万米ドルを供与しました。さらに、政府機関と主要企業との協力関係の増加が、新規抗ウイルス薬開発のための研究開発活動の成長を促進すると予想されています。例えば、2021年6月、Merck &Co., Inc.は、COVID-19治療用の治験用抗ウイルス薬であるモルヌピラビルの調達契約を米国政府と締結しました。同契約によると、モルヌピラビルが米国FDAの緊急使用承認または承認を受けた場合、同社は12億米ドルを受け取り、約170万コースの薬剤を米国政府に供給します。

さらに、市場主体は臨床検査の需要増に対応するため、戦略的な取り組みを行っています。大手企業は市場での地位を強化するため、地域企業の買収に取り組んでいます。このため、この地域ではプレーヤー間の競合が激しいです。同市場のプレーヤーは新製品の開発に注力しています。例えば、2023年6月現在、抗ウイルス薬開発のための臨床試験の第2相、第3相、第4相で900以上の研究が進行中です。さらに、2023年4月には、PharmaMar社がCOVID-19に罹患している免疫抑制患者の治療にプリチデプシンを使用するNereida臨床試験を開始し、スペイン、イタリア、フランス、ポーランド、ハンガリー、ギリシャ、ポルトガルで試験が承認されています。

抗ウイルス薬市場レポートハイライト

  • ブランドタイプは、その実証された有効性、安全性プロファイル、ヘルスケア当局による承認により広く採用されているため、2022年の市場を独占しました。
  • 薬剤クラス別では、HIV/AIDSなどの慢性疾患の蔓延により、効果的な治療薬に対するニーズが高まっていることから、プロテアーゼ阻害薬セグメントが2022年の市場を独占しました。
  • 流通チャネル別では、疾病に苦しむ人々の増加、急速な高齢化、入院患者数の増加により、病院薬局セグメントが2022年に最大の市場シェアを占めました。
  • 北米は、確立されたヘルスケアインフラの存在、ウイルス性疾患の高い有病率、治療薬の急速な進歩により、同市場における地域的地位を確立しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場動向と展望
  • 市場力学
    • ウイルス感染症の蔓延
    • ウイルス感染症に対する政府の取り組みの強化
    • 高齢者人口の増加
  • 市場抑制要因分析
    • 高額な治療費
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 タイプ別ビジネス分析

  • 抗ウイルス薬市場：タイプ変動分析
  • ブランド
  • ジェネリック

第5章 医薬品クラス別ビジネス分析

  • 抗ウイルス薬市場：薬剤クラスの変動分析
  • DNAポリメラーゼ阻害剤
  • 逆転写酵素阻害剤
  • プロテアーゼ阻害剤
  • ノイラミニダーゼ阻害剤
  • その他

第6章 流通チャネル別ビジネス分析

  • 抗ウイルス薬市場：流通チャネルの変動分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 用途別ビジネス分析

  • 抗ウイルス薬市場：アプリケーション変動分析
  • インフルエンザ
  • HIV
  • 肝炎
  • ヘルペス
  • その他

第8章 地域別ビジネス分析

  • 地域別抗ウイルス薬市場シェア、2022年および2030年
  • 北米
    • SWOT分析
    • 北米抗ウイルス薬市場、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • SWOT分析
    • 欧州の抗ウイルス薬市場、2018年から2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • SWOT分析
    • アジア太平洋地域の抗ウイルス薬市場、2018年から2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • SWOT分析
    • ラテンアメリカの抗ウイルス薬市場、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • SWOT分析
    • MEA抗ウイルス薬市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 企業の分類
  • 戦略マッピング
    • 新製品の発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 主要企業の市場シェア分析、2022年
  • 企業ヒートマップ分析
  • 企業プロファイル
    • F. HOFFMANN-LA ROCHE LTD.
    • GSK PLC.
    • ABBVIE, INC.
    • MERCK &CO., INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • CIPLA INC.
    • AUROBINDO PHARMA
    • DR. REDDY'S LABORATORIES LTD.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 Global Antiviral Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Canada Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 Europe Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Europe Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Germany Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 UK Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 UK Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 UK Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 UK Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 33 France Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 France Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 35 France Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 Italy Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Italy Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Italy Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 Spain Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Spain Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Denmark Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Denmark Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 49 Sweden Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Sweden Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 Norway Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Norway Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 China Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 63 China Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 China Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 China Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 66 Japan Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Japan Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Japan Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Japan Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 70 India Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 India Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 India Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 India Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 74 South Korea Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 76 South Korea Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 South Korea Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 78 Australia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 80 Australia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Australia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 82 Thailand Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Thailand Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Thailand Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Latin America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 91 Brazil Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 93 Brazil Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Brazil Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 95 Mexico Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 97 Mexico Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Mexico Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 99 Argentina Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 101 Argentina Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 102 Argentina Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 109 South Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 115 UAE Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 117 UAE Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Antiviral Drugs Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Antiviral Drugs Market: Type Movement Analysis
  • Fig. 17 Global Antiviral Drugs Market, by Branded, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antiviral Drugs Market, by Generics, 2018 - 2030 (USD Million)
  • Fig. 19 Global Antiviral Drugs Market: Drug Class Movement Analysis
  • Fig. 20 Global Antiviral Drugs Market, by DNA Polymerase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 21 Global Antiviral Drugs Market, by Reverse Transcriptase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 22 Global Antiviral Drugs Market, by Protease Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 23 Global Antiviral Drugs Market, by Neuraminidase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 24 Global Antiviral Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Global Antiviral Drugs Market: Distribution Channel Movement Analysis
  • Fig. 26 Global Antiviral Drugs Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 27 Global Antiviral Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global Antiviral Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2022 & 2030
  • Fig. 31 Global Antiviral Drugs Market: Region Movement Analysis
  • Fig. 32 North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-389-8

Antiviral Drugs Market Growth & Trends:

The global antiviral drugs market size is expected to reach USD 62.05 billion by 2030, registering a CAGR of -1.99% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This is attributed to the rising prevalence of viral diseases and growing government initiatives pertaining to the development of novel therapeutics to reduce the spread of infections. Furthermore, an increase in R&D efforts and the expansion of more recent & updated details, such as vaccinations and combined therapy, are projected to propel the growth of the market. Potential viral pandemics highlight the need for broad-spectrum antiviral drugs, such as direct-acting antivirals, that can be immediately deployed on a massive scale to halt viral spread until suitable vaccinations are created. Introducing blockbuster therapeutics for antiviral drugs has been transformative in treating various viral infections.

These drugs have demonstrated significant efficacy, widespread use, and substantial revenue generation for pharmaceutical companies.One prominent example is the introduction of Direct-acting Antivirals (DAAs) for the treatment of hepatitis C drugs, such as Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (sofosbuvir/velpatasvir), revolutionized the field by providing high cure rates, shorter treatment durations, and fewer side effects compared to previous therapies. These drugs achieved blockbuster status due to their effectiveness in curing hepatitis C and addressing a significant unmet medical need. Government initiatives for antiviral drugs include funding for R&D, streamlining regulatory processes for approval and emergency use authorizations, strategic stockpiling for preparedness, and collaborations with industry & academic institutions to accelerate development and ensure accessibility of effective antiviral treatments.

For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, granted around USD 577 million to launch nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Moreover, increasing collaborations between government bodies and key players are anticipated to fuel the growth of R&D activities for developing novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million drug courses to the U.S. government if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Furthermore, market entities are undertaking strategic initiatives to address the growing demand for clinical tests. Major players are involved in the acquisition of regional players to strengthen their position in the market. Thus, there is significant competition among players in this region. Players in the market are focusing on developing new products. For instance, as of June 2023, over 900 studies are ongoing in phases 2, 3, and 4 of clinical trials for antiviral drug development. Moreover, in April 2023, PharmaMar initiated the Nereida clinical trial using plitidepsin for the treatment of immunosuppressed patients suffering from COVID-19, with trials being approved in Spain, Italy, France, Poland, Hungary, Greece, and Portugal.

Antiviral Drugs Market Report Highlights:

  • The branded type segment dominated the market in 2022 as they are widely adopted due to their proven efficacy, safety profile, and endorsement by healthcare authorities
  • On the basis of drug class, the protease inhibitors segmentdominated the market in 2022 owing to the rising need for effective therapeutics due to the increasing prevalence of chronic diseases, such as HIV/AIDS
  • Based on distribution channel, the hospital pharmacy segment held the largest market share in 2022owing to an increasing number of people suffering from diseases, a rapidly aging population, and a growing number of hospitalizations
  • North America has established a strong regional position in the market due to the presence of well-established healthcare infrastructure,a high prevalence of viral diseases, and rapid advancements in therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing prevalence of viral infections
    • 3.4.2. Increasing government initiatives for viral infections
    • 3.4.3. Increasing geriatric population
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Antiviral Drugs Market: Type Movement Analysis
  • 4.2. Branded
    • 4.2.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.3. Generics
    • 4.3.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Antiviral Drugs Market: Drug Class Movement Analysis
  • 5.2. DNA Polymerase Inhibitors
    • 5.2.1. DNA Polymerase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.3. Reverse Transcriptase Inhibitors
    • 5.3.1. Reverse Transcriptase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.4. Protease Inhibitors
    • 5.4.1. Protease Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Neuraminidase Inhibitors
    • 5.5.1. Neuraminidase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Antiviral Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Antiviral Drugs Market: Application Movement Analysis
  • 7.2. Influenza
    • 7.2.1. Influenza Market, 2018 - 2030 (USD Million)
  • 7.3. HIV
    • 7.3.1. HIV Market, 2018 - 2030 (USD Million)
  • 7.4. Hepatitis
    • 7.4.1. Hepatitis Market, 2018 - 2030 (USD Million)
  • 7.5. Herpes
    • 7.5.1. Herpes Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antiviral Drugs Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. U.S. Antiviral drugs Market, 2018 - 2030 (USD MILLION)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.4. UK
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. France Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Reimbursement Scenario
      • 8.3.10.6. Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. China Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. India Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Reimbursement Scenario
      • 8.4.8.6. Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Reimbursement Scenario
      • 8.5.5.6. Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Reimbursement Scenario
      • 8.6.6.6. Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Product Launch
    • 9.2.2. Partnership
    • 9.2.3. Acquisition
    • 9.2.4. Collabboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2022
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. F. HOFFMANN-LA ROCHE LTD.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GSK PLC.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. ABBVIE, INC.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. MERCK & CO., INC.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. JOHNSON & JOHNSON SERVICES, INC.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BRISTOL-MYERS SQUIBB COMPANY
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. CIPLA INC.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AUROBINDO PHARMA
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. DR. REDDY'S LABORATORIES LTD.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives